5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation

Pulmonary vascular emergencies and chronic sleep-related breathing disorders require prompt recognition and evidence-based risk stratification. ABIM exam questions rigorously evaluate the sequential diagnostic algorithm for pulmonary embolism, advanced hemodynamic classifications of pulmonary hypertension, guideline-directed targeted therapeutics, and the clinical management of obstructive sleep apnea versus obesity hypoventilation syndrome.

1. Acute Pulmonary Embolism (PE): Pathophysiology & Diagnostics

Pulmonary embolism is the third leading cause of cardiovascular mortality worldwide. Emboli typically originate in the deep venous system of the lower extremities (iliac, femoral, popliteal veins) and occlude branches of the pulmonary arterial bed.

Pathophysiologic Cascade

• Right Ventricular (RV) Failure: Occlusion of >30–50% of the pulmonary vascular bed abruptly increases RV afterload -> acute RV dilation, hypokinesis, and ischemia -> leftward bowing of the interventricular septum (D-shaped LV on short-axis echo) -> impaired LV diastolic filling -> decreased stroke volume, systemic hypotension, cardiogenic shock, and pulseless electrical activity (PEA) arrest.
• Gas Exchange Abnormalities: (1) Increased alveolar dead space (areas with ventilation but absent perfusion, V/Q = infinity); (2) Right-to-left intrapulmonary and intracardiac shunting (via patent foramen ovale reopening); (3) V/Q mismatch and reflex bronchoconstriction due to inflammatory mediator release (serotonin, thromboxane A2).

Stepwise Diagnostic Algorithm

Clinical Decision Rules & Scoring Systems

1. Wells Clinical Prediction Rule for PE:
   • Clinical signs/symptoms of DVT (+3.0 points)
   • Alternative diagnosis less likely than PE (+3.0 points)
   • Heart rate > 100 beats/min (+1.5 points)
   • Immobilization (>=3 days) or surgery within past 4 weeks (+1.5 points)
   • Previous objectively diagnosed DVT or PE (+1.5 points)
   • Hemoptysis (+1.0 point)
   • Active malignancy with treatment within 6 months or palliative (+1.0 point)
   • Two-Tier Stratification: PE Unlikely (<=4.0 points); PE Likely (>4.0 points).
   • Three-Tier Stratification: Low risk (0–1 point); Intermediate risk (2–6 points); High risk (>=7 points).
2. PERC Rule (Pulmonary Embolism Rule-Out Criteria):
   • Applied only to patients with LOW pre-test probability (Wells <2). If ALL 8 criteria are met, the probability of PE is <1% and PE is ruled out without laboratory or imaging tests:
     1. Age < 50 years
     2. Pulse < 100 beats/min
     3. SaO2 >= 95% on room air
     4. No prior DVT or PE
     5. No recent surgery or trauma within 4 weeks
     6. No hemoptysis
     7. No exogenous estrogen use (OCPs, HRT)
     8. No unilateral lower extremity swelling
3. Age-Adjusted D-Dimer Cutoff:
   • In patients aged > 50 years with low or intermediate clinical probability, use the age-adjusted formula: Cutoff = Age (years) x 10 mcg/L (fibrinogen equivalent units) or ng/mL. (e.g., for a 75-year-old, cutoff is 750 mcg/L rather than standard 500 mcg/L). Increases specificity by ~20% without compromising sensitivity.
4. Imaging Modalities:
   • CT Pulmonary Angiography (CTPA): First-line test of choice in stable patients.
   • V/Q Lung Scan: Diagnostic test of choice when CTPA is contraindicated (severe renal impairment with eGFR < 30 mL/min/1.73m2, severe anaphylactoid iodinated contrast allergy, or pregnancy with a normal baseline chest radiograph). Interpreted via modified PIOPED criteria: A normal V/Q scan excludes PE; a high-probability scan with high clinical suspicion confirms PE; indeterminate/non-diagnostic scans require further imaging (e.g., lower extremity venous duplex ultrasound).

2. Risk Stratification & Acute PE Management

Therapeutic management is dictated strictly by hemodynamic stability, RV strain, and myocardial biomarker release.

Clinical Risk Categories

Anticoagulation Selection & Duration

1. Direct Oral Anticoagulants (DOACs): First-line treatment for acute VTE in patients without contraindications:
   • Apixaban: 10 mg PO BID for 7 days, then 5 mg PO BID.
   • Rivaroxaban: 15 mg PO BID with food for 21 days, then 20 mg PO daily.
   • Dabigatran / Edoxaban: Requires initial 5–10 days of parenteral anticoagulation (LMWH/UFH) prior to oral transition.
2. Special Patient Populations:
   • Antiphospholipid Syndrome (APLS): In patients with high-risk "triple-positive" APLS (lupus anticoagulant + anticardiolipin + anti-beta-2-glycoprotein I), Warfarin with a target INR 2.0–3.0 is the anticoagulant of choice. The TRAPS trial demonstrated that DOACs (Rivaroxaban) significantly increase arterial thromboembolic events (stroke, MI) compared to Warfarin; DOACs are contraindicated in triple-positive APLS.
   • Cancer-Associated Thrombosis (CAT): Oral factor Xa inhibitors (Apixaban, Rivaroxaban, Edoxaban) or LMWH (Enoxaparin 1 mg/kg SC q12h). In patients with unresected gastrointestinal or genitourinary luminal malignancies, LMWH or Apixaban is preferred due to lower mucosal bleeding rates.
   • Severe Renal Impairment (CrCl < 15–30 mL/min): IV Unfractionated Heparin transitioned to Warfarin (target INR 2.0–3.0) is preferred.
3. Duration of Anticoagulation:
   • Provoked PE by a major transient risk factor (major surgery, trauma, hospitalization >=3 days): Exactly 3 months of therapeutic anticoagulation.
   • Unprovoked PE, recurrent VTE, or persistent major risk factors: Indefinite (extended) anticoagulation with periodic reassessment of risk-benefit ratio.
4. Inferior Vena Cava (IVC) Filter Indications:
   • IVC filters do not reduce long-term mortality and increase recurrent DVT risk. Retrievable filters are indicated strictly for:
     1. Absolute contraindication to therapeutic anticoagulation in acute VTE (e.g., active major internal bleeding, recent hemorrhagic stroke).
     2. Recurrent objectively confirmed PE despite proven therapeutic anticoagulation.